Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan-Poly (Lactic Glycolic Acid) Nanoparticles

Author(s): Fatima Redah Alassaif, Eman Redah Alassaif, Amit Kumar Kaushik and Jeevitha Dhanapal*

Volume 17, Issue 1, 2023

Published on: 17 March, 2022

Page: [74 - 82] Pages: 9

DOI: 10.2174/1872210516666220111160341

Price: $65

conference banner
Abstract

Objective: The present article aimed to enhance the therapeutic efficacy of carboplatin (CP) using the formulation of chitosan-poly (lactic glycolic acid) nanoparticles (CS-PLGA NPs).

Methods: Nanoparticles were synthesized by an ionic gelation method and were characterized for their morphology, particle size, and surface potential measurements by TEM and zeta sizer. This study was highlighted for the evaluation of drug entrapment, loading and in vitro drug release capabilities of the prepared nanoparticles by spectrophotometric analysis. The stability study was also conducted after 3 months for their particle size, zeta potential, drug loading and encapsulation efficiencies. Further, ovarian cancer cell line PEO1 was used to evaluate the toxicity and efficacy of nano-formulation by MTT assay. Additionally, the study was evaluated for apoptosis using flow cytometric analysis.

Results: The CS-PLGA-CP NPs were uniform and spherical in shape. The particle size and zeta potential of CS-PLGA-CP NPs were measured to be 156 ±6.8 nm and +52 ±2.4 mV, respectively. High encapsulation (87.4 ± 4.5%) and controlled retention capacities confirmed the efficiency of the prepared nanoparticles in a time and dose-dependent manner. The cytotoxicity assay results also showed that CS-PLGA-CP NPs have a high efficiency on PEO1 cells compared to the free drug. The flow cytometric result showed 64.25% of the PEO1 cells were apoptotic, and 8.42% were necrotic when treated with CS-PLGA-CP NPs.

Conclusion: Chitosan-PLGA combinational polymeric nanoparticles were not only steady but also non-toxic. Our experiments revealed that the chitosan-PLGA nanoparticles could be used as a challenging vehicle candidate for drug delivery for the therapeutic treatment of ovarian cancer.

Keywords: Chitosan, carboplatin, nanoparticles, ovarian cancer, poly (lactic glycolic acid), PEO1.

« Previous Next »
Graphical Abstract

[1]
Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012; 31: 14.
[http://dx.doi.org/10.1186/1756-9966-31-14] [PMID: 22330607]
[2]
Arab M, Khayamzadeh M, Tehranian A, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer 2010; 47(3): 322-7.
[http://dx.doi.org/10.4103/0019-509X.64721] [PMID: 20587911]
[3]
Lambert LA. Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 2015; 65(4): 284-98.
[http://dx.doi.org/10.3322/caac.21277] [PMID: 25940594]
[4]
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12(4): 237-51.
[http://dx.doi.org/10.1038/nrc3237] [PMID: 22437869]
[5]
Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386(9990): 249-57.
[http://dx.doi.org/10.1016/S0140-6736(14)62223-6] [PMID: 26002111]
[6]
Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363(10): 943-53.
[http://dx.doi.org/10.1056/NEJMoa0908806] [PMID: 20818904]
[7]
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334(1): 1-6.
[http://dx.doi.org/10.1056/NEJM199601043340101] [PMID: 7494563]
[8]
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384(9951): 1376-88.
[http://dx.doi.org/10.1016/S0140-6736(13)62146-7] [PMID: 24767708]
[9]
Poy D, Ebrahimi Shahemabadi H, Akbarzadeh A. Moradi-Sardareh Hemen, Ebrahimifar M. Carboplatin liposomal nanoparticles: preparation, characterization and cytotoxicity effects on lung cancer in vitro environment. Int J Pol Mat Poly Biomat 2017; 67: 367-70.
[http://dx.doi.org/10.1080/00914037.2017.1332624]
[10]
Amiri B, Ebrahimi-Far M, Saffari Z, Akbarzadeh A, Soleimani E, Chiani M. Preparation, characterization and cytotoxicity of silibinin- containing nanoniosomes in t47d human breast carcinoma cells. Asian Pac J Cancer 2016; 17(8): 3835-8.
[PMID: 27644625]
[11]
Rostaminasab S, Noori S, Yaghmaei B, Rostaminasab Dolatabad M, Toofani Milani A, Mohammadian M. Anti-tumor immunostimulatory effect of sitosterol from Salvia atropatana on tumor bearing mice. Adv Biores 2015; 6: 133-40.
[12]
Sajjadiyan SZ, Hiva G, Attabak TM, et al. Preparation of silibinin loaded pegylatedniosomal nanoparticles and investigation of its effect on MCF-10A human breast cancer cell line. Pharm Lett 2016; 8: 70-5.
[13]
Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: Are there real alternatives? Chin J Cancer 2015; 34(1): 17-27.
[http://dx.doi.org/10.5732/cjc.014.10274] [PMID: 25556615]
[14]
Ando Y, Shimokata T, Yasuda Y, Hasegawa Y. Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci 2014; 76(1-2): 1-9.
[PMID: 25129986]
[15]
Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 2010; 28(30): 4568-74.
[http://dx.doi.org/10.1200/JCO.2010.29.3597] [PMID: 20855828]
[16]
Lakshmanan V-K, Snima KS, Bumgardner JD, Nair SV, Jayakumar R. Chitosan-based nanoparticles in cancer therapy Chitosan for biomaterials I. Berlin: Springer 2011; pp. 55-91.
[http://dx.doi.org/10.1007/12_2011_132]
[17]
Patrulea V, Ostafe V, Borchard G, Jordan O. Chitosan as a starting material for wound healing applications. Eur J Pharm Biopharm 2015; 97(Pt B): 417-26.
[http://dx.doi.org/10.1016/j.ejpb.2015.08.004] [PMID: 26614560]
[18]
Pereira P, Pedrosa SS, Correia A, et al. Biocompatibility of a self-assembled glycol chitosan nanogel. Toxicol In Vitro 2015; 29(3): 638-46.
[http://dx.doi.org/10.1016/j.tiv.2014.11.004] [PMID: 25482991]
[19]
Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 1999; 20(2): 175-82.
[http://dx.doi.org/10.1016/S0142-9612(98)00159-8] [PMID: 10022787]
[20]
Mourya V, Inamdar NN. Chitosan-modifications and applications: Opportunities galore. React Funct Polym 2008; 68: 1013-51.
[http://dx.doi.org/10.1016/j.reactfunctpolym.2008.03.002]
[21]
Gorzelanny C. Pöppelmann B, Pappelbaum K, Moerschbacher BM, Schneider SW. Human macrophage activation triggered by chitotriosidase-mediated chitin and chitosan degradation. Biomaterials 2010; 31(33): 8556-63.
[http://dx.doi.org/10.1016/j.biomaterials.2010.07.100] [PMID: 20797781]
[22]
Seferian PG, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000; 19(6): 661-8.
[http://dx.doi.org/10.1016/S0264-410X(00)00248-6] [PMID: 11090719]
[23]
Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010; 62(1): 3-11.
[http://dx.doi.org/10.1016/j.addr.2009.09.004] [PMID: 19800377]
[24]
Chen P-G, Huang Z-H, Sun Z, et al. Chitosan nanoparticles based nanovaccines for cancer immunotherapy. Pure Appl Chem 2017; 89: 931-9.
[http://dx.doi.org/10.1515/pac-2016-0913]
[25]
Shi G-N, Zhang C-N, Xu R, et al. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Biomaterials 2017; 113: 191-202.
[http://dx.doi.org/10.1016/j.biomaterials.2016.10.047] [PMID: 27816821]
[26]
Ahmad N, Ahmad R, Al Qatifi S, Alessa M, Al Hajji H, Sarafroz M. A bioanalytical UHPLC based method used for the quantification of Thymoquinone-loaded-PLGA-nanoparticles in the treatment of epilepsy. BMC Chem 2020; 14(1): 10.
[http://dx.doi.org/10.1186/s13065-020-0664-x] [PMID: 32083254]
[27]
Ahmad N, Ahmad R, Almakhamel MZ, et al. A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. Artif Cells Nanomed Biotechnol 2020; 48(1): 749-62.
[http://dx.doi.org/10.1080/21691401.2020.1748640] [PMID: 32272850]
[28]
Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ. Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res 2012; 94(1): 41-8.
[http://dx.doi.org/10.1016/j.exer.2011.11.003] [PMID: 22123068]
[29]
Alibolandi M, Ramezani M, Abnous K, et al. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer. J Control Release 2015; 209: 88-100.
[http://dx.doi.org/10.1016/j.jconrel.2015.04.026] [PMID: 25912964]
[30]
Sudha T, Bharali DJ, Yalcin M, et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomedicine 2017; 12: 1305-15.
[http://dx.doi.org/10.2147/IJN.S123742] [PMID: 28243091]
[31]
Mehdizadeh M, Rouhani H, Sepehri N, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy. Artif Cells Nanomed Biotechnol 2017; 45(3): 495-504.
[http://dx.doi.org/10.1080/21691401.2016.1178130] [PMID: 27137460]
[32]
Davis PJ, Incerpi S, Lin H-Y, Tang HY, Sudha T, Mousa SA. Thyroid hormone and P-glycoprotein in tumor cells. BioMed Res Int 2015; 2015: 168427.
[http://dx.doi.org/10.1155/2015/168427] [PMID: 25866761]
[33]
Calvo P. Remu ̃n ́an-L ́opez C,, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosanpolyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997; 63: 125-32.
[http://dx.doi.org/10.1002/(SICI)1097-4628(19970103)63:1<125:AID-APP13>3.0.CO;2-4]
[34]
Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11(9): 1358-61.
[http://dx.doi.org/10.1023/A:1018967116988] [PMID: 7816770]
[35]
Lin WC, Yu DG, Yang MC. pH-sensitive polyelectrolyte complex gel microspheres composed of chitosan/sodium tripolyphosphate/dextran sulfate: Swelling kinetics and drug delivery properties. Colloids Surf B Biointerfaces 2005; 44(2-3): 143-51.
[http://dx.doi.org/10.1016/j.colsurfb.2005.06.010] [PMID: 16054345]
[36]
Anitha A, Deepagan VG, Divya Rani VV, Menon D, Nair SV, Jayakumar R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate–chitosan nanoparticles. Carbohydr Polym 2011; 84: 1158-64.
[http://dx.doi.org/10.1016/j.carbpol.2011.01.005]
[37]
Dhanapal J, Balaraman Ravindrran M. Chitosan/poly (lactic acid)- coated piceatannol nanoparticles exert an in vitro apoptosis activity on liver, lung and breast cancer cell lines. Artif Cells Nanomed Biotechnol 2018; 46(sup1): 274-82.
[http://dx.doi.org/10.1080/21691401.2017.1422130] [PMID: 29298541]
[38]
Mehdi SJ, Ahmad A, Irshad M, Nikhat M, Rizvi MA. Cytotoxic effect of Carvacrol on human cervical cancer cells. Biol Med Biol Med 2011; 3: 307-12.
[39]
Alfandari J, Shnitman Magal S, Jackman A, Schlegel R, Gonen P, Sherman L. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 1999; 257(2): 383-96.
[http://dx.doi.org/10.1006/viro.1999.9675] [PMID: 10329549]
[40]
Kirby BJ, Hasselbrink EF Jr. Zeta potential of microfluidic substrates: 1. Theory, experimental techniques, and effects on separations. Electrophoresis 2004; 25(2): 187-202.
[http://dx.doi.org/10.1002/elps.200305754] [PMID: 14743473]
[41]
Jaganathan KS, Rao YU, Singh P, et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: A comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 2005; 294(1-2): 23-32.
[http://dx.doi.org/10.1016/j.ijpharm.2004.12.026] [PMID: 15814228]
[42]
Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol Photochem Rev 2009; 10: 81-95.
[http://dx.doi.org/10.1016/j.jphotochemrev.2009.05.001]
[43]
Jayakumar R, Nwe N, Tokura S, Tamura H. Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 2007; 40(3): 175-81.
[http://dx.doi.org/10.1016/j.ijbiomac.2006.06.021] [PMID: 16893564]
[44]
Mahmoudi M, Zamani S, Rabe T, Ahi A, Emami SA, et al. Evaluation of the cytotoxic activity of different Artemisia khorasanica samples on cancer cell lines. Pharmacologyonline 2009; 2: 778-86.
[45]
Strasser A, O’Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-45.
[http://dx.doi.org/10.1146/annurev.biochem.69.1.217] [PMID: 10966458]
[46]
Osborne BA. Apoptosis and the maintenance of homoeostasis in the immune system. Curr Opin Immunol 1996; 8(2): 245-54.
[http://dx.doi.org/10.1016/S0952-7915(96)80063-X] [PMID: 8725948]
[47]
Sriram MI, Kanth SBM, Kalishwaralal K, Gurunathan S. Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model. Int J Nanomedicine 2010; 5: 753-62.
[PMID: 21042421]

Rights & Permissions Print Cite
Article Metrics
69
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy